[go: up one dir, main page]

EA201992326A1 - Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака - Google Patents

Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака

Info

Publication number
EA201992326A1
EA201992326A1 EA201992326A EA201992326A EA201992326A1 EA 201992326 A1 EA201992326 A1 EA 201992326A1 EA 201992326 A EA201992326 A EA 201992326A EA 201992326 A EA201992326 A EA 201992326A EA 201992326 A1 EA201992326 A1 EA 201992326A1
Authority
EA
Eurasian Patent Office
Prior art keywords
stem cells
methods
cancer
csc
compositions
Prior art date
Application number
EA201992326A
Other languages
English (en)
Inventor
Дэвид Чиреш
Хироми Веттерстен
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Publication of EA201992326A1 publication Critical patent/EA201992326A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предоставлены композиции и способы лечения или ослабления рака путем направленного воздействия на экспрессируемые на клеточной поверхности полипептиды v3 (avb3) в раковых стволовых клетках (CSC) для уничтожения CSC, таким образом, для лечения, ослабления или замедления развития рака, вызванного, или инициированного, или поддерживаемого раковыми или опухолевыми клетками или раковыми стволовыми клетками (CSC), экспрессирующими полипептиды v3 на своих клеточных поверхностях. Предоставлены композиции и способы для осуществления направленного воздействия и уничтожения v3-положительных раковых стволовых клеток (CSC) и лечения лекарственно-устойчивых форм рака. В альтернативных вариантах осуществления в композициях и способах, предлагаемых в настоящей заявке, используют антитело, которое может специфически связываться с человеческим v3 и которое содержит Fc-участок, способный опосредовать антителозависимую клеточно-опосредованную цитотоксичность (ADCC), уничтожающую раковые или опухолевые клетки посредством макрофагов; например, используют гуманизированное анти-v3 антитело, которое модифицировано путем включения сконструированного Fc-участка, специфически связывающегося с макрофагами человека.
EA201992326A 2017-03-31 2018-03-30 Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака EA201992326A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479768P 2017-03-31 2017-03-31
PCT/US2018/025470 WO2018183894A1 (en) 2017-03-31 2018-03-30 Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers

Publications (1)

Publication Number Publication Date
EA201992326A1 true EA201992326A1 (ru) 2020-03-13

Family

ID=63676868

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992326A EA201992326A1 (ru) 2017-03-31 2018-03-30 Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака

Country Status (12)

Country Link
US (2) US20200109205A1 (ru)
EP (2) EP4353318A3 (ru)
JP (2) JP2020512978A (ru)
KR (1) KR102630070B1 (ru)
CN (1) CN110662559A (ru)
AU (1) AU2018243670B2 (ru)
BR (1) BR112019020451A2 (ru)
CA (1) CA3058458A1 (ru)
EA (1) EA201992326A1 (ru)
IL (1) IL269746A (ru)
MX (1) MX2019011717A (ru)
WO (1) WO2018183894A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113557246B (zh) 2019-07-24 2023-09-01 韩国基础科学支援研究院 靶向αvβ3整联蛋白的单域抗体
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers
IL296576A (en) * 2020-04-23 2022-11-01 Alpha Beta Holdings Llc Compounds and methods for treating cancer
CN112626118B (zh) * 2020-11-12 2023-06-23 清华-伯克利深圳学院筹备办公室 细胞株及其应用
CN118284622A (zh) * 2021-09-30 2024-07-02 阿尔法贝塔控股有限责任公司 治疗癌症的组合物和方法
CN115960160B (zh) * 2021-10-12 2024-07-16 南京大学 活细胞膜整合素αvβ3聚糖的原位糖链延长方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6500924B1 (en) * 1996-05-31 2002-12-31 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CA2294900A1 (en) 1997-07-02 1999-01-14 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
ES2313883T3 (es) * 1999-02-12 2009-03-16 The Scripps Research Institute Procedimientos para el tratamiento de tumores y metastasis utilizando una combinacion de terapias antiangiogenicas e inmunoterapias.
AU766570B2 (en) 1999-04-23 2003-10-16 Mitsubishi Chemical Corporation Antibody and polyalkylene glycol-bonded liposome
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7858117B2 (en) 2002-02-21 2010-12-28 Novosom Ag Amphoteric liposomes and their use
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
EP1547581A1 (en) 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
CA2549966A1 (en) 2003-12-24 2005-07-07 Ltt Bio-Pharma Co., Ltd. Drug-containing nanoparticle, process for producing the same and parenterally administered preparation from the nanoparticle
AU2005219413A1 (en) 2004-03-02 2005-09-15 Massachusetts Institute Of Technology Nanocell drug delivery system
US20070082042A1 (en) 2004-08-06 2007-04-12 Deok-Hoon Park Multiple-layered liposome and preparation method thereof
AU2005277567A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
EP1896071B1 (en) * 2005-06-30 2015-04-29 Janssen Biotech, Inc. Methods and compositions with enhanced therapeutic activity
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
US20080088046A1 (en) 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
CA2629815C (en) * 2005-11-14 2014-08-12 University Of Southern California Integrin-binding small molecules
US20080089928A1 (en) 2006-06-13 2008-04-17 Stavroula Sofou Liposome drug carriers with ph-sensitivity
US20110319335A1 (en) * 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
US20140154264A1 (en) * 2011-06-02 2014-06-05 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
WO2013152313A1 (en) 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
US20160319032A1 (en) * 2013-10-01 2016-11-03 Medlmmune Limited Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer
WO2015068847A1 (ja) * 2013-11-11 2015-05-14 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
WO2016100858A1 (en) * 2014-12-18 2016-06-23 The Regents Of The University Of California Methods for inhibiting alpha-v beta-3 expression on cancer stem cells and inhibiting progression to a cancer stem cell phenotype
WO2021026024A1 (en) * 2019-08-02 2021-02-11 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3 -positive cancer stem cells (cscs) and treating drug resistant and metastatic cancers

Also Published As

Publication number Publication date
WO2018183894A1 (en) 2018-10-04
EP3600422A1 (en) 2020-02-05
CN110662559A (zh) 2020-01-07
EP3600422B1 (en) 2023-10-18
JP2021095423A (ja) 2021-06-24
JP2020512978A (ja) 2020-04-30
KR102630070B1 (ko) 2024-01-26
US20200109205A1 (en) 2020-04-09
MX2019011717A (es) 2019-12-16
AU2018243670B2 (en) 2025-05-01
BR112019020451A2 (pt) 2020-04-28
EP3600422A4 (en) 2021-01-13
EP4353318A3 (en) 2024-07-17
KR20190133205A (ko) 2019-12-02
IL269746A (en) 2019-11-28
EP4353318A2 (en) 2024-04-17
AU2018243670A1 (en) 2019-10-31
US20240067733A1 (en) 2024-02-29
CA3058458A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
EA201992326A1 (ru) Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
CL2020002446A1 (es) Anticuerpos contra mica y/o micb y sus usos
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
MX2018014950A (es) Terapia de combinacion.
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
CR20160186A (es) Anticuerpos anti-cd38 específicos para tratar cánceres humanos
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
MY207784A (en) Anti-cd73 antibodies
ZA202405748B (en) Universal abt compounds and uses thereof
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
WO2019112347A3 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
EA202090947A1 (ru) Композиции и способы для истощения cd5+ клеток
EA202091747A1 (ru) Составы антитела b7-h4
MX2021000783A (es) Anticuerpos humanizados contra psma.
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2020005473A (es) Anticuerpos humanizados que se dirigen al factor tisular humano.
MX2024007390A (es) Anticuerpo completamente humanizado y receptor de antigeno quimerico (car) dirigido al subtipo d de la familia c5 del receptor acoplado a proteina g (gprc5d) y usos del mismo.
MX2022006147A (es) Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.
MX2024003779A (es) Agentes de union dirigidos a celulas tumorales que expresan trop2.
EA201491352A1 (ru) Способ лечения рака груди
WO2019173902A8 (en) Combination of cd47 blockade therapy and a cd38 antibody
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
PH12022550006A1 (en) Cd38-binding agents and uses thereof